Ceprotin Treatment Registry
The Ceprotin Treatment Registry, sponsored by Baxalta (now part of Shire), aims to gather comprehensive data on the treatment and safety outcomes of patients with severe congenital Protein C deficiency receiving Ceprotin. Given the rarity of this condition, the registry serves as a critical tool for understanding treatment efficacy and safety, potentially enhancing market positioning for Ceprotin in the niche coagulation disorder space. The completion of this observational study may provide valuable insights for future product development and regulatory submissions, while also reinforcing Shire's commitment to rare disease management. The competitive landscape includes other therapies targeting coagulation disorders, necessitating ongoing vigilance regarding emerging treatments and market entrants.
Indication: Protein C Deficiency
Modality: protein therapy
Target: Protein C deficiency management through Protein C Concentrate (Human)
Sponsor: Baxalta now part of Shire
Source URL: ClinicalTrials.gov
Source updated: Detailed source ingestion pending
Ingested: Jul 16, 2026
Model: trialsignal-ai-v1
Validation: validated
Matched by target_normalized: Protein C deficiency management through Protein C Concentrate (Human)
View original source fields
Condition raw: Protein C Deficiency
Condition normalized: Protein C Deficiency
Modality raw: protein therapy
Modality normalized: protein therapy
Target raw: Protein C deficiency management through Protein C Concentrate (Human)
Target normalized: Protein C deficiency management through Protein C Concentrate (Human)